Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Chemotherapy-induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol.

Brierley DI, Harman JR, Giallourou N, Leishman E, Roashan AE, Mellows BAD, Bradshaw HB, Swann JR, Patel K, Whalley BJ, Williams CM.

J Cachexia Sarcopenia Muscle. 2019 Apr 29. doi: 10.1002/jcsm.12426. [Epub ahead of print]

2.

O-Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity.

Caprioglio D, Allegrone G, Pollastro F, Valera S, Lopatriello A, Collado JA, Munoz E, Appendino G, Taglialatela-Scafati O.

Planta Med. 2019 Apr 1. doi: 10.1055/a-0883-5383. [Epub ahead of print]

PMID:
30934093
3.

Use of 13C-qNMR Spectroscopy for the Analysis of Non-Psychoactive Cannabinoids in Fibre-Type Cannabis sativa L. (Hemp).

Marchetti L, Brighenti V, Rossi MC, Sperlea J, Pellati F, Bertelli D.

Molecules. 2019 Mar 22;24(6). pii: E1138. doi: 10.3390/molecules24061138.

4.

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.

Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I.

Transl Neurodegener. 2019 Mar 8;8:9. doi: 10.1186/s40035-019-0148-x. eCollection 2019.

5.

First application of atmospheric-pressure chemical ionization gas chromatography tandem mass spectrometry to the determination of cannabinoids in serum.

Gottardo R, Sorio D, Ballotari M, Tagliaro F.

J Chromatogr A. 2019 Apr 26;1591:147-154. doi: 10.1016/j.chroma.2019.01.041. Epub 2019 Jan 14.

PMID:
30679047
6.

Validation of a liquid chromatography-tandem mass spectrometry method for analyzing cannabinoids in oral fluid.

Sobolesky PM, Smith BE, Hubbard JA, Stone J, Marcotte TD, Grelotti DJ, Grant I, Fitzgerald RL.

Clin Chim Acta. 2019 Apr;491:30-38. doi: 10.1016/j.cca.2019.01.002. Epub 2019 Jan 4.

PMID:
30615854
7.

Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.

D'Aniello E, Fellous T, Iannotti FA, Gentile A, Allarà M, Balestrieri F, Gray R, Amodeo P, Vitale RM, Di Marzo V.

Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):586-597. doi: 10.1016/j.bbagen.2019.01.002. Epub 2019 Jan 3.

PMID:
30611848
8.

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients.

Roslawski MJ, Remmel RP, Karanam A, Leppik IE, Marino SE, Birnbaum AK.

Ther Drug Monit. 2019 Jun;41(3):357-370. doi: 10.1097/FTD.0000000000000583.

PMID:
30520828
9.

Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

Scheidweiler KB, Barnes AJ.

Methods Mol Biol. 2019;1872:11-22. doi: 10.1007/978-1-4939-8823-5_2.

PMID:
30350275
10.

Iodine-mediated cyclization of cannabigerol (CBG) expands the cannabinoid biological and chemical space.

Lopatriello A, Caprioglio D, Minassi A, Schiano Moriello A, Formisano C, De Petrocellis L, Appendino G, Taglialatela-Scafati O.

Bioorg Med Chem. 2018 Aug 15;26(15):4532-4536. doi: 10.1016/j.bmc.2018.07.044. Epub 2018 Jul 27.

PMID:
30077611
11.

Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis.

Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido M, Fernández-Ruiz J, Muñoz E, de Lago E.

Biochem Pharmacol. 2018 Nov;157:217-226. doi: 10.1016/j.bcp.2018.07.049. Epub 2018 Aug 1.

PMID:
30076846
12.

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid.

Gugliandolo A, Pollastro F, Grassi G, Bramanti P, Mazzon E.

Int J Mol Sci. 2018 Jul 8;19(7). pii: E1992. doi: 10.3390/ijms19071992.

13.

Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes.

Navarro G, Varani K, Reyes-Resina I, Sánchez de Medina V, Rivas-Santisteban R, Sánchez-Carnerero Callado C, Vincenzi F, Casano S, Ferreiro-Vera C, Canela EI, Borea PA, Nadal X, Franco R.

Front Pharmacol. 2018 Jun 21;9:632. doi: 10.3389/fphar.2018.00632. eCollection 2018.

14.

Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

Arnold WR, Weigle AT, Das A.

J Inorg Biochem. 2018 Jul;184:88-99. doi: 10.1016/j.jinorgbio.2018.03.016. Epub 2018 Apr 7.

15.

Reprint of: Amorfrutin-type phytocannabinoids from Helichrysum umbraculigerum.

Pollastro F, De Petrocellis L, Schiano-Moriello A, Chianese G, Heyman H, Appendino G, Taglialatela-Scafati O.

Fitoterapia. 2018 Apr;126:35-39. doi: 10.1016/j.fitote.2018.04.002. Epub 2018 Apr 11. No abstract available.

PMID:
29655820
16.

Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis.

Petrosino S, Verde R, Vaia M, Allarà M, Iuvone T, Di Marzo V.

J Pharmacol Exp Ther. 2018 Jun;365(3):652-663. doi: 10.1124/jpet.117.244368. Epub 2018 Apr 9.

PMID:
29632236
17.

The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

Couch DG, Maudslay H, Doleman B, Lund JN, O'Sullivan SE.

Inflamm Bowel Dis. 2018 Mar 19;24(4):680-697. doi: 10.1093/ibd/izy014.

PMID:
29562280
18.

Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol.

Smeriglio A, Giofrè SV, Galati EM, Monforte MT, Cicero N, D'Angelo V, Grassi G, Circosta C.

Fitoterapia. 2018 Jun;127:101-108. doi: 10.1016/j.fitote.2018.02.002. Epub 2018 Feb 7.

PMID:
29427593
19.

Detection and Quantification of Cannabinoids in Extracts of Cannabis sativa Roots Using LC-MS/MS.

Gul W, Gul SW, Chandra S, Lata H, Ibrahim EA, ElSohly MA.

Planta Med. 2018 Mar;84(4):267-271. doi: 10.1055/s-0044-100798. Epub 2018 Jan 22.

PMID:
29359294
20.

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.

García C, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo-Garo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Luz Bellido M, García-Arencibia M, Ruth Pazos M, Muñoz E, Fernández-Ruiz J.

J Neuroinflammation. 2018 Jan 16;15(1):19. doi: 10.1186/s12974-018-1060-5.

Supplemental Content

Loading ...
Support Center